Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | UQCRB | P14927 | 2/20 | 0.50 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14419945 | 0.84 | LMNA (0.56) | LMNAMEN1KMT2ACA2CA12 | |
| SCHEMBL8395741 | 0.83 | KMT2A (0.54) | LMNAMEN1KMT2ACA2CA12 | |
| SCHEMBL27723796 | 0.82 | CA1 (0.64) | LMNACA2CA12CA1CA9 | |
| SCHEMBL11314864 | 0.80 | CA2 (0.56) | LMNAMEN1KMT2ACA2CA12 | |
| SCHEMBL7020553 | 0.80 | SMN1; SMN2 (0.64) | LMNACA2CA12CA1CA9 | |
| SCHEMBL3812298 | 0.80 | LMNA (0.52) | LMNAMEN1KMT2ACA2CA12 | |
| SCHEMBL1592323 | 0.78 | UQCRB (0.76) | LMNAMEN1KMT2ACA2CA12 | |
| SCHEMBL29048604 | 0.77 | LMNA (0.48) | LMNAMEN1KMT2ACA2CA12 | |
| SCHEMBL21420105 | 0.77 | MEN1 (0.58) | LMNAMEN1KMT2ACA2CA12 | |
| SCHEMBL7493770 | 0.76 | LMNA (0.67) | LMNAMEN1KMT2ACA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527878-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527878-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160009748-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009748-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-01-14 | — | — | US | disclosed |
| US-9120744-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120744-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120744-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-01 | — | — | US | disclosed |
| US-20100137194-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2010-06-03 | — | — | US | disclosed |
| US-20100137194-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2010-06-03 | — | — | US | disclosed |
| US-20100137194-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2010-06-03 | — | — | US | disclosed |
| US-5712018-A | FLOOR COVERING | CONGOLEUM CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| US-5531944-A | VINYL FLOORING | CONGOLEUM CORPORATION (US) | 1996-07-02 | — | — | US | disclosed |
| WO-1995017973-A1 | MULTI-LEVEL, EXPANDED RESINOUS PRODUCT | CONGOLEUM CORPORATION (US) | 1995-07-06 | — | — | WO | disclosed |
| US-5336693-A | Aqueous solution or dispersion of film-forming resin, blowing agent modifier, colors, for printing on foamable polymeric coverings | CONGOLEUM CORPORATION (US) | 1994-08-09 | — | — | US | disclosed |
| EP-0386147-A4 | EMBOSSING COMPOSITION FOR PREPARING TEXTURED POLYMERIC MATERIALS | — | 1991-07-10 | — | — | EP | disclosed |
| EP-0386147-A1 | EMBOSSING COMPOSITION FOR PREPARING TEXTURED POLYMERIC MATERIALS | CONGOLEUM CORPORATION (US) | 1990-09-12 | — | — | EP | disclosed |
| WO-1989004341-A1 | EMBOSSING COMPOSITION FOR PREPARING TEXTURED POLYMERIC MATERIALS | CONGOLEUM CORPORATION (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0044277-B1 | PRINTING INK AND ITS USE IN THE MANUFACTURE OF TEXTURED, FOAMED RESINOUS MATERIALS | CIBA-GEIGY AG (CH) | 1985-08-28 | — | — | EP | disclosed |
| EP-0012967-B1 | (2,4,5-TRIMETHYLACETANILIDO) IMINODIACETATE, TECHNETIUM-99M-LABELLED (2,4,5-TRIMETHYLACETANILIDO)-IMINODIACETATE FOR DIAGNOSING THE FUNCTIONING OF THE LIVER AND PROCESSES FOR PREPARING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-12-28 | — | — | EP | disclosed |
| EP-0044277-A2 | Printing ink and its use in the manufacture of textured, foamed resinous materials | CIBA-GEIGY AG (CH) | 1982-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137194-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | SERPINE1, PLAT, SERPINB1 | SERPINE1 1/4885LMNA 1156/4885MEN1 1398/4885 |
| US-20160009748-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | SERPINE1, PLAT, SERPINB1 | SERPINE1 1/4885LMNA 1156/4885MEN1 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.